



Perma-Fix Medical Provides Second Quarter Business Update

Schedules Investor Webcast for September 1 at 2:00 PM Central European Time

Wroclaw – September 1, 2016 – Perma-Fix Medical S.A. (WAR: PFM) today provided a general business update for the second quarter ended June 30, 2016. The Company also announced it will host a business update call at 2:00 PM Central European time (8:00 a.m. Eastern time) on Thursday, September 1, 2016, via webcast on the company's website: www.medical-isotope.com.

Stephen Belcher, Chief Executive Officer of Perma-Fix Medical S.A. stated, "We continue to make progress preparing our 505(b)(2) for submission to the U.S. FDA. Since we are focusing on our regulatory filings, we have not had many public announcements. Nevertheless, we are making steady progress on a number of very important fronts. We are in active discussions with potential investors, strategic partners, distributors and customers. We still have a goal to eventually list on the NASDAQ in the U.S., but knowing that the filing of our 505(b)(2) would positively impact our valuation in the U.S., we plan to delay our listing until after 2016. In the meantime we are evaluating a variety of other near-term and long-term options that we believe will maximize value for shareholders. We are fully committed to executing our business model and do not believe the current value of our stock in Poland is reflective of the tremendous value we have created. Based on feedback from the industry, we strongly believe our new process to produce Technetium-99m has the potential to transform the radiopharmaceutical industry. We look forward to providing additional updates in the near future."

The conference call can be accessed via a live Internet webcast on the Company's website at www.medical-isotope.com. A webcast replay of the conference call will be accessible on the Company's website at www.medical-isotope.com for 90 days.

About Perma-Fix Medical

Perma-Fix Medical S.A. was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

Contacts:

Justyna Gudaszewska or David K. Waldman
Crescendo Communications Europe Sp. z o.o
Tel: (+48) 693 354 580
Email : pfm@crescendo-ir.com